Statute Details
- Title: Pharmacists Disciplinary Rules
- Act Code: PRA2007-R3
- Type: Subsidiary legislation (sl)
- Authorising Act: Pharmacists Registration Act (Cap. 230), Section 21
- Legislative instrument: G.N. No. S 20/1981
- Revised edition: Revised Edition 1990 (25th March 1992)
- Status: Current version as at 27 Mar 2026
- Commencement date: Not stated in the provided extract
- Key procedural focus: Complaint handling, statutory declaration requirement, Board inquiry procedure, document access, privacy, evidence under oath, findings, and penalties
- Notable provisions (from extract): Rules 2–6 (complaints and Board decision), Rules 8–12 (notice, timing, privacy), Rules 11–16 (documents, evidence, conduct, findings), Rules 19–21 (multi-pharmacist inquiries and penalties)
What Is This Legislation About?
The Pharmacists Disciplinary Rules set out the procedural framework for how Singapore’s professional regulator (the Board) deals with allegations of misconduct or other grounds for disciplinary action against registered pharmacists. In practical terms, the Rules govern what happens after a complaint is made: how the complaint is assessed, what information must be provided, how an inquiry is convened, what procedural safeguards apply to the pharmacist, and how the Board reaches and records its decisions.
Although the Rules are procedural rather than substantive, they are crucial for practitioners because disciplinary outcomes often turn on process—particularly whether the complaint is properly supported, whether the pharmacist receives adequate notice and access to documents, whether the inquiry is conducted fairly, and how evidence is handled. The Rules also address confidentiality: inquiries are held in private, with limited discretion for publication of findings.
The Rules operate alongside the Pharmacists Registration Act, which provides the substantive grounds for disciplinary action and the Board’s powers. The Rules then translate those powers into a step-by-step procedure. For example, the Board may decide to take no action, issue a warning, direct removal of a pharmacist’s name from the register (where permitted under the Act), or hold an inquiry. The Rules also specify how the Board’s representative presents the case and how the pharmacist may participate.
What Are the Key Provisions?
1. Complaint intake and the Board’s initial consideration (Rules 2–4). The process begins with the Board’s duty to consider every written complaint against a pharmacist. The Rules allow the “complaint” to be a report, including reports of conviction for certain offences or reports that a pharmacist’s name should be removed from the register on specified grounds under the Act. Where an alleged offence is involved, the report may be submitted by specified authorities (such as the Registrar of the Supreme Court or Subordinate Courts, or an Inspector of the Ministry of Health). This matters for practitioners because it clarifies that the Board’s jurisdiction is triggered by written complaints/reports from defined sources, not only by private complainants.
Once the Board receives a complaint, the Registrar must send the pharmacist a copy of the complaint and a copy of any statutory declaration furnished under Rule 5. The pharmacist is then asked to provide any explanation to the Board. This early stage is often strategically important: it is the pharmacist’s first formal opportunity to shape the Board’s view before an inquiry is ordered.
2. Statutory declaration requirement for allegations of improper act or conduct (Rule 5). A central procedural safeguard is that, where a pharmacist is alleged to have been guilty of an improper act or conduct, the Board must not proceed further under the Rules unless a statutory declaration has been furnished to the Board’s satisfaction. The statutory declaration must state: (a) the complainant’s name, address, and occupation; (b) the grounds of the complaint; and (c) the evidence of the alleged improper act or conduct. The Board may waive the statutory declaration in its discretion if the allegation is made by a public officer or the Board’s solicitor.
For lawyers, this requirement is often a threshold issue. If the statutory declaration is missing, defective, or not “to the Board’s satisfaction,” the Board may be constrained from proceeding. Conversely, if the Board waives it, practitioners should consider whether the waiver is properly exercised and whether the underlying allegation is sufficiently particularised to enable meaningful response.
3. Board’s decision on further proceedings (Rule 6). After considering the complaint, the statutory declaration (if any), and the pharmacist’s explanation, the Board may decide among several outcomes: (a) no action; (b) issue a warning; (c) direct removal of the pharmacist’s name from the register under specified provisions of the Act; or (d) hold an inquiry under the Rules. Before directing removal under the relevant paragraph, the Board must give the pharmacist a reasonable opportunity of being heard. This “reasonable opportunity” requirement is a key fairness element and should be treated as a procedural right that can be invoked in any challenge to the Board’s decision-making.
4. Notice, timing, and service for an inquiry (Rules 7–9). If the Board orders an inquiry, it may be represented by an advocate and solicitor or a public officer as the Board’s representative. The representative must serve the pharmacist with a notice specifying the charge(s) and the time, date, and place of the inquiry. The inquiry is generally not earlier than 28 days after the date of the notice unless the pharmacist agrees otherwise. The notice must be sent by registered post to the pharmacist’s last known address. Where there is a complainant, a copy of the complaint must also be sent to the complainant.
These provisions are highly relevant to procedural fairness and to any later dispute about whether the pharmacist had adequate time and proper notice to prepare. Practitioners should ensure that service requirements are satisfied and that the charges are clearly articulated in the notice.
5. Document access and confidentiality (Rules 10–12). The Rules provide for document handling in two ways. First, at the pharmacist’s request, the Board’s representative must send the pharmacist a copy of every document relating to the matter under inquiry that is in the Board’s possession, subject to an express limitation: the representative is not compelled to produce copies of correspondence between the representative and the Board. Second, the pharmacist and the representative must be permitted access to information contained in any document at a reasonable time before the document is tendered in evidence at the inquiry.
In addition, inquiries are held in private. The Board may, in its discretion, publish a report of its findings at the end of the hearing. This balances confidentiality with accountability. For counsel, the privacy rule affects media strategy, public communications, and the management of any parallel proceedings.
6. Evidence, representation, and the inquiry procedure (Rules 13–16). The Board may require the Board’s representative or the pharmacist to produce documents relating to the matter that are in their possession. Evidence is given under oath or affirmation by persons attending the inquiry. The pharmacist may appear in person or be represented by counsel, by a member of a pharmaceutical/professional organisation of which he is a member, or by a family member.
The procedure at the inquiry is set out in Rule 15. If the pharmacist does not appear, the Board may proceed after being satisfied that notice was served. The procedure includes: reading the charge(s) to the pharmacist; allowing objections to the charge(s); requiring the Board’s representative to present facts and adduce evidence; allowing the pharmacist to give evidence and cross-examine witnesses; allowing the Board to question and cross-examine; and allowing closing addresses by both sides. The Board may determine that a charge is groundless and stop further proceedings on that charge.
Importantly, Rule 15(4) provides that the Board is not bound to act in a formal manner and is not bound by the Evidence Act or other evidence rules. However, this does not remove the requirement that evidence be given under oath. Practitioners should therefore prepare for a more flexible evidentiary approach, while still ensuring that key documents and witness testimony are properly marshalled and that objections are raised where appropriate.
At the conclusion, the Board considers whether each charge has been proved to its satisfaction. If any charge is proved, the pharmacist may address the Board in mitigation and adduce evidence of character. This mitigation stage is often where counsel can contextualise conduct, demonstrate rehabilitation, and present professional standing or corrective steps.
7. Multi-pharmacist inquiries and penalties (Rules 19–21). The extract indicates provisions for inquiries into conduct of two or more pharmacists at the Board’s discretion. This can be significant where allegations arise from the same incident, system, or set of events. The Rules also provide for penalties and, ultimately, removal of a pharmacist’s name from the register (Rule 21). While the provided text truncates the later sections, the structure suggests a graduated disciplinary framework culminating in removal where warranted by the Act and the Board’s findings.
How Is This Legislation Structured?
The Rules are structured as a sequence of procedural steps, beginning with citation (Rule 1), moving through complaint receipt and preliminary decision-making (Rules 2–6), and then detailing the mechanics of an inquiry (Rules 7–18). The inquiry portion covers representation (Rule 7), notice and timing (Rule 8), postponement (Rule 9), document provision and access (Rules 10–11), privacy (Rule 12), evidence under oath (Rule 13), representation of the pharmacist (Rule 14), and the conduct of the inquiry (Rule 15). The Rules then address findings (Rule 16), postponed judgment (Rule 17), and absence of a Board member (Rule 18). Finally, the Rules cover special circumstances such as joint inquiries (Rule 19) and the range of penalties and register removal (Rules 20–21).
Who Does This Legislation Apply To?
The Rules apply to registered pharmacists who are the subject of written complaints or reports to the Board alleging improper acts or conduct, or other grounds that may justify disciplinary action under the Pharmacists Registration Act. The procedural protections and obligations in the Rules are directed at both the pharmacist under inquiry and the Board’s representative.
The Rules also indirectly apply to complainants and relevant authorities because they govern what must be provided to trigger further proceedings (notably the statutory declaration requirement in Rule 5) and how complaints/reports are transmitted. Where the allegation is based on conviction or specified grounds under the Act, the Rules clarify who may submit the report to the Board.
Why Is This Legislation Important?
For practitioners, the Pharmacists Disciplinary Rules are important because they operationalise the Board’s disciplinary jurisdiction and define the fairness and preparation requirements that can determine outcomes. The statutory declaration threshold (Rule 5) and the Board’s obligation to consider explanations (Rule 4) create early procedural checkpoints. If these are not complied with, it may affect whether the Board can lawfully proceed to an inquiry or direct removal.
The Rules also provide practical guidance on how to run a disciplinary hearing: the notice must specify charges and be served by registered post; the pharmacist generally has at least 28 days to prepare; document access is guaranteed at a reasonable time before evidence is tendered; and evidence is taken under oath even though the Board is not bound by the strict Evidence Act regime. This combination—flexibility in procedure, but formal safeguards for notice and oath—means counsel must be ready to argue both procedural objections and evidential weight.
Finally, the privacy rule (Rule 12) and the discretion to publish findings affect reputational risk and communications strategy. Counsel should advise clients on confidentiality expectations and on how disciplinary findings may later be reported, even if the inquiry itself is private.
Related Legislation
- Pharmacists Registration Act (Cap. 230) — particularly the provisions on disciplinary grounds and the Board’s powers (notably Section 21 as the authorising provision for these Rules)
- Evidence Act (Cap. 97) — referenced in the Rules as not binding on the Board’s inquiry procedure
Source Documents
This article provides an overview of the Pharmacists Disciplinary Rules for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.